Combination Therapy with Immune Checkpoint Inhibitors and Histone Deacetylase Inhibitors or Alkylating Agents.

Publication

Combination Therapy with Immune Checkpoint Inhibitors and Histone Deacetylase Inhibitors or Alkylating Agents.

Journal Paper/Review - Jul 22, 2024

Jörger Markus, Koster Kira-Lee, Janik Tomas, de Jong Floris A

Citation

Jörger M, Koster K, Janik T, de Jong F. Combination Therapy with Immune Checkpoint Inhibitors and Histone Deacetylase Inhibitors or Alkylating Agents. Cancer Manag Res 2024; 16:855-869.

Type

Journal Paper/Review (English)

Journal

Cancer Manag Res 2024; 16

Publication Date

Jul 22, 2024

Issn Print

1179-1322

Pages

855-869

Brief description/objective

Immune checkpoint inhibitors (CPIs) have been widely adopted in a number of early and advanced malignancies. Histone deacetylase inhibitors (HDACis) and alkylating agents (AAs) have been suggested to potentiate the actions of CPIs on tumor cells. We conducted a comprehensive literature review to explore the potential synergistic activity between CPIs, AAs, and HDACis.